Treatment of Antibody-Mediated Rejection (ABMR) With CarBel

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Kidney Transplant Rejection
Interventions
BIOLOGICAL

Carfilzomib

Administered by intravenous infusion over 60 minutes.

BIOLOGICAL

Belatacept

Administered by intravenous infusion over 30 minutes.

Trial Locations (10)

10016

NOT_YET_RECRUITING

NYU Langone Health, New York

27710

RECRUITING

Duke University, Durham

35294

NOT_YET_RECRUITING

University of Alabama Medical Center, Birmingham

44195

NOT_YET_RECRUITING

Cleveland Clinic, Cleveland

45267

NOT_YET_RECRUITING

University of Cincinnati, Cincinnati

53726

NOT_YET_RECRUITING

University of Wisconsin - Madison, Madison

60611

NOT_YET_RECRUITING

Northwestern University, Feinberg School of Medicine, Chicago

63110

RECRUITING

Washington University, St Louis

85054

RECRUITING

Mayo Clinic Arizona, Phoenix

90095

NOT_YET_RECRUITING

UCLA, Los Angeles

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH